Del Barrio A S, Rguez-Mariscal M, Martínez J A, Larralde J
Departamento de Nutrición y Bromatología, Universidad de País Vasco, Vitoria, Spain.
Growth Dev Aging. 1992 Fall;56(3):141-8.
The non-selective beta-adrenergic agonist, metaproterenol, administered orally (2 ppm and 20 ppm) and subcutaneously (0.1 mg/Kg/d) for 21 days to young male rats induced no changes in animal growth or food intake. However, the rats treated with metaproterenol showed increased muscle gastrocnemius weight, which was accompanied by a muscle hyperplasia (DNA content increase) and a reduction in cellular size (protein/DNA ratio decrease). The beta-agonist did not affect liver growth or liver cellularity when assessed through the nucleic acid content. The increase in muscle mass was attributed, at least in part, to a reduction in protein breakdown as muscular cathepsin A activity was significantly lower in beta-agonist treated rats.
非选择性β-肾上腺素能激动剂间羟异丙肾上腺素，以2 ppm和20 ppm的剂量口服以及以0.1 mg/Kg/d的剂量皮下注射给年轻雄性大鼠21天，未引起动物生长或食物摄入量的变化。然而，用间羟异丙肾上腺素治疗的大鼠腓肠肌重量增加，同时伴有肌肉增生（DNA含量增加）和细胞大小减小（蛋白质/DNA比率降低）。通过核酸含量评估时，β-激动剂不影响肝脏生长或肝细胞数量。肌肉质量的增加至少部分归因于蛋白质分解减少，因为在β-激动剂治疗的大鼠中，肌肉组织蛋白酶A活性显著降低。
